Within-host population dynamics of antibiotic-resistant M. tuberculosis

Mathematical Medicine and Biology

Volumn 24, Issue 1, 2007, Pages 35-56

  Alavez Ramírez, Justino ^a   Castellanos, J Rogelio Avendano ^b   Esteva, Lourdes ^c   Flores, José Antonio ^c   Fuentes Allen, José Luis ^d   García Ramos, Gisela ^e   Gómez, Guillermo ^c   López Estrada, Jesús ^c  

^a UNIVERSIDAD JUÁREZ AUTÓNOMA DE TABASCO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^e UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Antimicrobial resistance; Isoniazid; Mathematical model; Rifampin; Tuberculosis

Indexed keywords

ANTIBIOTICS; BACTERIA; DRUG THERAPY; DYNAMICS; POPULATION DYNAMICS; POPULATION STATISTICS;

ANTIMICROBIAL DRUG; ANTIMICROBIAL RESISTANCES; EQUILIBRIUM STABILITY; IMMUNE RESPONSE; M. TUBERCULOSIS; MODEL STABILITY; MYCOBACTERIUM TUBERCULOSIS; RESISTANT BACTERIA; RIFAMPIN; TUBERCULOSIS;

IMMUNE SYSTEM;

ANTIBIOTIC AGENT; ISONIAZID; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL IMMUNITY; DRUG EFFICACY; HUMAN; IMMUNE DEFICIENCY; MATHEMATICAL MODEL; MICROBIAL POPULATION DYNAMICS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SIMULATION; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 33847646662     PISSN: 14778599     EISSN: 14778602     Source Type: Journal    
DOI: 10.1093/imammb/dql026     Document Type: Article

References (47)

1. American Thoracic Society & Center for Disease Control and Prevention (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am. J. Respir. Crit. Care Med., 161, S221-S247.
2. Billington, O. J., Mchugh, T. D. & Gullespie, S. H. (1999) Physiological cost of tifampicin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 43, 1866-1869.
3. Björkholm, B., Sjölund, M., Falk, P. G., Berg, O. G., Engstrand, L. & Andersson, D. I. (2001) Mutation frequency and biological cost of antibiotic resistance in Heliobacter pylori. Proc. Natl. Acad. Sci. USA, 98, 14607-14612.
4. Blower, S. M. & Chou, T. (2004) Modeling the emergence of the "hot zones": Tuberculosis and the amplification dynamics of drug resistance. Nat. Med., 10, 1111-1116.
5. Blower, S. M., Small, P. M. & Hopewell, P. C. (1996) Control strategies for tuberculosis epidemics: New models for old problems. Science, 273, 497-500.
6. Blumberg, H. M., Leonard Jr., M. K. & Jasmer, R. M. (2005) Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA, 293, 2776-2784.
7. Chan, K., Knaak, T., Satkamp, L., Humbert, O., Falkow, S. & Ramakrishnan, L. (2002) Complex pattern of Mycobacterium marinum gene expression during long-term granulomatous infection. PNAS, 99, 3920-3925.
8. Cohen, T., Sommers, B. & Murray, M. (2003) The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect. Dis., 3, 13-21.
9. Cohen, T. & Murray, M. (2004) Modelling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nature Medicine, 10, 1117-1121.
10. DeAngelis, C. D. & Flanigin, A. (2005) Tuberculosis - a global problem requiring a global solution. JAMA, 293, 2793-2794.
11. Dye, C. & Espinal, M. A. (2001) Will tuberculosis become resistant to all antibiotics? Proc. R. Soc. Lond. B, 268, 45-52.
12. Dye, C., Scheele, S., Dolin, P., Pathania, V. & Raviglione, M. C. (1999) Consensus statement. Global burden of tuberculosis, estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA, 282, 677-686.
13. Dye, C. & Williams, B. G. (2000) Criteria for the control of drug-resistant tuberculosis. Proc. Natl. Acad. Sci. USA, 97, 8180-8185.
14. Fountain, F. F., Tolley, E., Chrisman, C. R. & Self, T. H. (2005) Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection. Chest, 128, 116-123.
15. Gammack, D., Ganguli S., Marino, S., Segovia-Juarez, J. & Kirschner, D. E. (2005) Macrophage response to Mycobacterium tuberculosis infection. J. Math. Biol., 48, 218-242.
16. Grant, A. D., Charalambous, S., Fielding, K. L., Day, J. H., Corbett, E. L., Chaisson, R. E., De Cock, K. M., Hayes, R. J. & Churchyard, G. Y. (2005) Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: A novel randomized incremental recruitment study. JAMA, 293, 2719-2725.
17. Haase, A. T. (1999) Population biology of HIV-I infection; viral and CD4+ T cell demography and dynamics in lymphatic tissues. Annu. Rev. Immunol., 17, 625-656.
18. Hall, R. J., Gubbins, S. & Gilligan, C. A. (2004) Invasion of drug and pesticide resistance is determined by a trade-off between treatment efficacy and relative fitness. Bull. Math. Biol., 66, 825-840.
19. Harkin, T. J. & Condos, R. (2004) Management of multidrug-resistant tuberculosis. Tuberculosis (W. N. Rom & S. M. Garay eds). New York: Lippincott Williams and Wilkins, pp. 729-738.
20. Heym, B., Honore, N., Truffot-Pernot, C., Banerjee, A., Schurra, C., Jacobs, W. R. Jr., Van Embden, J. D., Grosset, J. H. & Cole, S. T. (1994) Implication of multidrug resistance for the future of short course chemotherapy of tuberculosis: A molecular level. Lancet, 334, 293-298.
21. Hoal-Van Helden, E. G., Hon, D., Lewis, L. A., Beyers, N. & Van Helden, P. D. (2001) Mycobacterial growth in human macrophages: Variation according to donor, inoculum and bacterial strain. Cell Biol. Int., 25, 71-81.
22. Kang, Y. A., Lee, H. W., Yoon, H. I., Cho, B., Han, S. K., Young, S. S., Shim, Y. S. & Yim, J. J. (2005) Discrepancy between the tuberculin skin test and the whole-blood interferon. Assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA, 293, 2756-2761.
23. Kirschner, D. E. (1999) Dynamics of co-infection with M. tuberculosis and HIV-1. Theor Popul. Biol., 55, 94-109.
24. Li Q., Whalen, C. C., Albert, J. M., Larkin, R., Zukowski, L., Cave, M. D. & Silver, R. F. (2002) Differences in rate and variability of intracellular growth of a panel of Mycobacterium tuberculosis clinical isolates within monocyte model. Infect. Immun., 70, 6489-6493.
25. Lipsitch, M. & Levin, B. R. (1998) Population dynamics of tuberculosis treatment: Mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int. J. Tuberc. Lung Dis., 2, 187-199.
26. Marino, S. & Kirschner, D. E. (2004) The human immune response to Mycobacterium tuberculosis in lung and lymph node. J. Theor. Biol., 227, 463-486.
27. May, R. (1976) Theoretical Ecology. Principles and Application. Sunderland, MA: Sinauer Associates, Inc.
28. Mitchinson, D. A. (1985) Mechanism of drug action in short course chemotherapy. Bull. Int. Union Tuberc., 64, 30-37.
29. Nettleman, M. D. (2005) Multidrug-resistant tuberculosis: News from the front. JAMA, 293, 2788-2790.
30. North, R. J., Ryan, L., LaCource, R., Morgues, T. & Goodrich, M. E. (1999) Growth rate of mycobacteria in mice as an unreliable indicator of mycobacterial virulence. Infect. Immun., 67, 5483-5485.
31. Pablo-Mendez, A., Raviglioni, M. C., Laszlo, A., Binkin, N., Rieder, H. L., Bustreeo, F., Cohn, D. L., Lambregts-Van Weezen-Beek, C. S., Kim, S. J., Chaulet, P. & Nunn, P. (1998) Global surveillance for antituberculosis-drug resistance, 1994-1997. N. Engl. J. Med., 338, 1641-1649.
32. Parrish, N. M., Dick, J. D. & Bishai, W. R. (1998) Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol., 6, 107-112.
33. Rachman, H., Strong, M., Ulrichs, T., Grode, L., Schuch-Hardt, J., Mollenkopf, H., Kosmiadi, G. A., Eisenberg, D. & Kaufmann, S. H. E. (2006) Unique transcriptome signature in Mycobacterium tuberculosis in pulmonary tuberculosis. Infect. Immun., 74, 1233-1242.
34. Riska, P. F., Jacobs Jr., W. R. & Allan, D. (2000) Molecular determinants of drug resistance in tuberculosis. Int. J. Tuberc. Lung Dis., 4, 4-10.
35. Shimao, T. (1987) Drug resistance in tuberculosis control. Tubercle, 68, 5-15.
36. Steele, M. A., Burk, R. F. & Desprez, R. M. (1991) Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest, 99, 465-471.
37. Telenti, A. & Iseman, M. (2000) Drug-resistance tuberculosis. What do we know? Drugs, 59, 171-179.
38. Thompson, P. A. (1970) Characterization of the germination response to temperature of species and ecotypes. Nature, 225, 827-831.
39. Ulrischs, T. & Kaufmann, S. H. (2004) Cell-mediated immune response. Tuberculosis (W. N. Rom & S. M. Garay eds). New York: Lippincott Williams and Wilkins, pp. 251-267.
40. Werngren, J. & Hoffner, S. E. (2003) Drug-susceptible Mycobacterium tuberculosis Beijing genotype does not develop mutation-conferred resistance to rifampin at an elevated rate. J. Clin. Microbiol., 41, 1520-1524.
41. Whalen, C. C. (2005) Diagnosis of latent tuberculosis infection: Measure for measure. JAMA, 293, 2785-2787.
42. Wigginton, J. E. & Kirschner, D. E. (2001) A model to predict cell-mediated immune regulatory mechanisms during human infection with Mycobacterium tuberculosis. J. Immunol., 166, 1951-1967.
43. Williams, B. G. & Dye, C. (2003) Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science, 301, 1535-1537.
44. World Health Organization (1996) Global Report on Tuberculosis. Geneva, Switzerland: World Health Organization.
45. World Health Organization (2004) Global Tuberculosis Control: Surveillance, Planning, Financing. Geneva, Switzerland: World Health Organization.
46. Young, A. K., Hye, W. L., Ho, I. Y., Belong, C. H., Sung, K. H., Young-Soo, S. & Jae-Joon, Y. (2005) Discrepancy between the tuberculin skin test and the whole-blood interferon assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA, 293, 2756-2761.
47. Zhang, M. J., Gong, J., Yang, Z., Samtem, B., Cave, M. D. & Barnes, P. F. (1999) Enhanced capacity of a widespread strain of Mycobacterium tuberculosis to grow in human monocytes. J. Infect. Dis., 179, 1213-1217.